May 26, 2023
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Today, on 26 May 2023, the annual general meeting was held in Chosa Oncology AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and distribution of the company’s profit
The annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The annual general meeting also resolved to distribute the company’s profit in accordance with the proposal from the board meaning that no dividends are paid and that available funds are carried forward.
Discharge from liability for the members of the board and the CEO
The annual general meeting resolved to discharge the members of the board and the CEO from liability for the financial year 2022.
Election of board members and auditor as well as remuneration for the board members and auditor
The annual general meeting resolved in accordance with the proposal from Buhl Krone Holding ApS (the ”Proposer”) to re-elect Neil Goldsmith, Ingrid Atteryd Heiman, Lars Hedbys, Claus Frisenberg Pedersen and Ulla Hald Buhl as ordinary board members. Lars Hedbys was elected as new Chairman of the board. The current Chairman of the board Neil Goldsmith had declined re-election as Chairman of the board. Remuneration to the board shall be paid with SEK 150,000 to the Chairman of the board and with SEK 75,000 to each of the other board members. Board remuneration shall not be paid to Claus Frisenberg Pedersen and Ulla Hald Buhl.
Furthermore, the annual general meeting resolved, in accordance with the proposal from the Proposer, to re-elect Deloitte AB as auditor and that remuneration for the auditor shall be paid in accordance with customary norms and approved invoice. Deloitte AB has informed that Magnus Andersson will continue to be appointed as the responsible auditor.
Resolution on authorization regarding issues
The annual general meeting resolved, in accordance with the proposal from the board of directors, to authorize the board of directors, up until the next annual general meeting, at one or several occasions, with or without deviation from the shareholders’ preferential rights and with or without provisions regarding contribution in kind, set-off or other conditions, to issue shares, convertibles and/or warrants.
The reason for why a deviation from the shareholders’ preferential rights should be possible is to enable the company to source working capital, to be able to execute acquisitions of companies or operating assets as well as to enable issues to industrial partners within the framework of partnerships and alliances. To the extent that the authorization is used for an issue with deviation from the shareholders’ preferential rights, the issue shall take place on market terms.
Lund on 26 May 2023
Chosa Oncology AB (publ)